Daymark Wealth Partners, LLC Revance Therapeutics, Inc. Transaction History
Daymark Wealth Partners, LLC
- $2.95 Billion
- Q3 2024
A detailed history of Daymark Wealth Partners, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Daymark Wealth Partners, LLC holds 15,000 shares of RVNC stock, worth $38,550. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,000
Previous 76,000
80.26%
Holding current value
$38,550
Previous $195,000
80.51%
% of portfolio
0.0%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding RVNC
# of Institutions
234Shares Held
82.8MCall Options Held
680KPut Options Held
896K-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.73MShares$14.7 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA4.78MShares$12.3 Million0.0% of portfolio
-
Fil LTD Hamilton, D04.19MShares$10.8 Million0.01% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ4.16MShares$10.7 Million0.49% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...